APPLICATION
NDA220020
TYPE
NDA
ORIGINAL APPROVAL
2025-06-18
LATEST ACTION
2025-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
YEZTUGO · ReferencePrescription
LENACAPAVIR SODIUM EQ 300MG BASE · TABLET · ORAL
Approval history
2025-06-18Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · Original · priority — Label ↗AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.